ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Also NCI Cancels von Eschenbach’s Farewell Party, Returns Gift Contributions Amid Ethics Questions.

May 19, 2006

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012

ACCP Publishes Guidelines Recommending Low-Dose CT

May 31, 2013

TGen’s Trent To Lead Van Andel Institute

February 13, 2009

Firm Wins Patent For Method, Apparatus For Cryoablation.

December 15, 2000

NIH Guidelines Define Eligible Research Using Stem Cells.

September 8, 2000